Cogstate (ASX: CGS), Pureprofile (ASX: PPL) and Genetic Signatures (ASX: GSS) each recently updated the market on Q3 FY 2022 results.

The recent approval of Eisai’s Aduhelm has got the market’s attention, because it translates into higher profits for Cogstate.

Some stocks have high multiples and higher growth rates, others have lower multiples and lower growth rates. Here’s how I decided which one to choose.